Recursion to report Q2 2026 results on Aug 5

1 min read | Published on 29 Jul 2026, 08:26 PM |Updated on 29 Jul 2026, 08:26 PM

Reviewed by

Anirudha BScanX News Team

Key Highlights

Recursion Pharmaceuticals will release Q2 2026 financial results on August 5, 2026. An earnings call is scheduled for 8:00 AM ET, with live streaming available on social media platforms. The company continues to advance its AI-driven drug discovery pipeline.

*this image is generated using AI for illustrative purposes only.

Recursion Pharmaceuticals (NASDAQ: RXRX) will report its second quarter 2026 financial results and provide business updates on Wednesday, August 5, 2026, before the open of financial markets. The announcement marks the company’s latest disclosure of operational and financial performance for the period ended June 30, 2026.

The Salt Lake City-based TechBio firm will host an earnings call on August 5, 2026, at 8:00 AM ET (6:00 AM MT / 1:00 PM BST). The live stream will be broadcast via Recursion’s X, LinkedIn, and YouTube accounts. Investors, analysts, and the public can submit questions for the management team through a dedicated online form.

Earnings Call Details

Detail	Information
Date	August 5, 2026
Time	8:00 AM ET
Platform	Live stream on X, LinkedIn, YouTube
Q&A	Online submission form

Recursion is advancing a portfolio of investigational medicines across oncology, rare disease, neuroscience, and immunology. The company utilizes its Recursion OS, an AI-native drug discovery platform, to integrate biology, chemistry, and clinical development.

About Recursion

Recursion operates automated biology and chemistry laboratories in Salt Lake City, Utah, and Milton Park, Oxfordshire. These facilities generate proprietary data at industrial scale to support its drug discovery efforts. The company maintains additional offices in New York, Montréal, and London.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will the Q2 2026 financial results reflect the capital efficiency of Recursion's AI-native drug discovery platform compared to traditional biotech peers?

Which specific investigational medicines in oncology or rare disease are expected to reach pivotal clinical milestones following this earnings update?

Will Recursion provide updated guidance on cash runway and potential need for additional capital raising given its current burn rate?